Introduction: The risk of TB is increased in patients with chronic kidney disease (CKD) when compared with individuals with normal renal function. We aimed to determine tuberculin skin test (TST) response and the factors which might affect the response in patients with CKD undergoing dialysis in this study.
INTRODUCTION
Tuberculosis (TB) is a leading cause of infectious disease morbidity and mortality worldwide with many diagnostic uncertainties. 1 The risk of TB is increased in patients with chronic kidney diseases (CKDs) when compared with individuals with normal renal function. 2 It is known that uremia disrupts cellular immunity which is the most important mechanism in development of TB infection. The risk of TB is increased 10-25.3-fold in patients undergoing hemodialysis (HD). 3 In another study showed that the cumulative incidence of TB in patients with CKD was found to be 85 times the background rate in patients on HD. 4 Latent TB infection (LTBI) may progress to active disease in patients with CKD. In this case, the diagnosis of LTBI is very important. Tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) tests are used for indicating LTBI. TST is a test which is recommended in TB screening in patients with CKD. However, negative TST, is observed with a high rate, because uremic environment in these patients affects macrophage functions. 5 The World Health Organization (WHO) recommended that either IGRAs or TST should be used to test for LTBI in patient receiving HD. 6 According to our national guidelines reported that TST should be continued in our country. It is recommended that IGRA should be performed in people who are strongly considered TB infections and immunosuppressed or immunosuppressive treatment candidates of TST-negative (with booster). 7 The reaction to administered TST is a delayed (cellular) hypersensitivity reaction. T-cells sensitized by prior infection are recruited to the skin site where they release lymphokines. These lymphokines induce induration via local vasodilatation, edema, fibrin deposition, and recruitment of other inflammatory cells to the area. Thus, the immune system needs to be functional to mount a response to the tuberculin injected under the skin. 8 Several factors influence immun system in CKD, such as chronic inflammation, uremic toxin, malnutrition, vitamin D-parathyroid hormone axis alternation, and dialysis. 9, 10 Many studies have suggested that both innate and acquired immune systems are impaired in CKD. This condition involves the coexistence of chronic immune activation and suppression. 11 We aimed to determine TST response and the factors which might affect the response in patients with CKD undergoing dialysis in this study.
MATERIALS AND METHODS
It was designed as a prospective cross-sectional study. Ethical approval for the study was obtained. Four hundred and seven patients with CKD receiving HD from six different state hospitals were evaluated. The age, gender, and smoking status of the patients and their comorbidities were recorded by patient self-reports and data from the patient files. The number of Bacille Calmette-Guerin (BCG) scars were recorded by checking both shoulders. Duration of dialysis: Time which takes between from today to initiated hemodialysis therapy (year) C-Reactive Protein (CRP) (mg/dl); parathormone (PTH) (pg/dl); albumin (gr/dl), calcium (mg/dl), and phosphorous (mg/dl) levels; lymphocyte counts; and the presence of vitamin D treatment were registered from the patient files. Body mass index (BMI) and fat-free mass (FFM) values were measured with Tanita device (TBF-300, TANITA, Middlesex, UK). There were no patients known to be HIV positive, and no patients had a history of intravenous drug abuse.
Exclusion criteria were as follows: active or past history of treated TB, those who did not accept to participate in the study, those who were still being treated or followed by cancer or other autoimmune diseases and/or immunosupressive agents usage.
Inclusion criteria were patients with CKD undergoing dialysis.
Thirty-six patients were excluded according to abovementioned criteria and the study was conducted with the remaining 371 patients. Informed consent forms were obtained from all patients. Information about TST and administration procedures was explained to the patients who met the study inclusion criteria.
Administration procedure
0.1 ml tuberculin (5 tuberculin U) was withdrawn from a bottle containing protein-purified derivative after a 21 G injector needle was attached safely. The needle was proceeded approximately 3 mm in the epidermis with an angle of [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] by holding the selected area between the thumb and index finger tightly. Injection was administered by releasing the area which was held tightly and it was assumed that the injection was administered appropriately when a pale area of 6-10 cm occurred. The test was repeated with a similar method in another area 5 cm distant from the initial test area in patients with an induration less than 5 cm. The patients were told not to scratch the area, to keep the area clean and avoid creams, lotions and dressing.
Evaluation of the test
The transverse diameter (long axis of the forearm) of induration at the site of the injection and not redness was measured 72 hours after the application of tests. If there was no induration it was recorded as "0" (Anergy was defined as lack of response to all antigens). If induration was present, the value was recorded as mm.
Statistical methods
All of the data from the study were imported to a database formed by the Statistical Package for Social Sciences (SPSS) program V22 (IBM Corp, Armonk, New York), and statistical analysis was also done using the same program. Nominal variables were given by their frequencies and percentages and compared by cross tables. Independent groups were compared using a Chi-square test. Descriptive data are reported as mean and standard deviation (SD) or median and quartiles (Q), as appropriate, for continuous variables, or as frequency for ordinal or nominal data. The factors affecting TST were divided into two groups. Accordingly, TST ≤ 5 and TST > 5 were crossed. The factors affecting TST were investigated using the logistic regression analysis. For all the statistical comparison tests, the probability of a type 1 error was α = 0.05 and two sided. Differences between the groups were found to be statistically significant if the "P" value was below 0.05.
RESULTS
The study was conducted with a total of 371 patients (194 men and 177 women). The mean age was 61.3 ± 16.9 years in the female patients and 58.9 ± 14.7 years in the male patients. Comorbidities in these patients are shown in Table 1 . 179 patients (80 female and 99 male) were receiving vitamin D treatment (48%). As vitamin D treatment, paracalcitol was given to all patients. PTH level was 624 ± 351 in patients receiving vitamin D, those not receiving vitamin D 387 ± 441 (P < 0.001). The average TST was 6.99 ± 6.9. The demographic data and biochemical values of the patients included in the study are shown in Table 1 .
The prevalence of anergy associates with high PTH values. When analyzed according to quartiles of PTH values, it was detected a significancy among quartiles (P < 0.001) (Figure 1) .
For logistic regression analysis, the TST induration diameter was categorized into two groups as ≤5 mm and >5 mm. The mean, median, minimum, maximum, and interquartile ranges of the variables in these groups are shown in Table 2 .
A cut off of 130 pg/mL for PTH was used. 12 The variables which were included in the analysis are presented in Table 3 .
Gender (P = 0.084), vitamin D treatment and PTH remained in the final stage of the analysis and vitamin D intake and PTH levels were found to be statistically significant (P = 0.0001, 0.048) ( Table 4) .
DISCUSSION
In our study, it was detected that high PTH level and vitamin D intake effect on TST which reflects cellular immunity. However, low TST levels in patients taking vitamin D has not been clear on which depends vitamin D effects directly or being high PTH level fundamentally. In a study carried out in our country, mean TST levels were found to be 16.41 ± 6.56 over 60 years of age in general population. 13 In our study, the mean TST values were found as 6.99 ± 6.9. This study is very similar to our study in several aspects. The number of BCG scars of the study were distributed from 0 to 5 and conducted in the same region. When compared with this study, despite similar age range, the immune response to TST was observed to be low in patients with CKD in our study.
When the studies were examined, it was found that the frequency of anergy, which is below 5% in the general population, was found to be as high as 32% to 53% in these patients. 14, 15 We found that the rate of negative TST was 53.6% (22.9% was anergic) in the patients and the remaining was positive. When compared to these studies, anery rate in CKD was lower in our study. In patients with CKD, because of associated immunodeficiency, the reported rates of skin anergy to the TST vary but can be up to 50%, which explains to a low sensitivity for the test in this patient. 16 This is thought to be related to impaired cellular immunity associated with uremia. 17 When we investigated the factors associated with negative TST, we detected a statistically significant decrease in TST values of these patients who had an increased level of PTH and who received vitamin D treatment because of an increased PTH level. In the study conducted by Griveas et al., 34 patients undergoing HD was considered and two groups (normal and increased PTH levels) were compared and it was found that increased PTH caused changes in cellular immunity by affecting lymphocyte functions. In patients with increased PTH levels, CD2, CD3, CD3/CD8, and CD4/CD8 levels were detected to be higher compared to patients with normal PTH levels. 18 All these are surface differentiation antigens and they bring about releasing of some cytokines and inflammatory factors such as IL-4 and 5. In our study, TST values were found to be lower in the patients who received vitamin D treatment (markedly increased PTH levels) and increased PTH levels. It was found that the other variables had no effect on TST responses in the initial stage of the analysis. Even though it was not clear, low levels of TST in these patients taking vitamin D treatment may be related to high PTH rather than vitamin D effects, which was used to suppress high level of PTH. Because, mounting evidence indicates that the usefulness of vitamin D extends beyond its classical role in maintenance of mineral homeostasis and the present use of active vitamin D includes the treatment of secondary hyperparathyroidism in CKD, which include modulation of the innate and adaptive immune responses. 19, 20 Some studies reported that treatment with Vitamin D can alter immune function in CKD patients, enhance Th 2 cell differentiation, 21 decrease IL-6, IL-8, IL-1, and TNF-α expression as an antiinflammatory effect. 22 A large historical cohort study showed that while elevated serum calcium, phosphorus, and PTH were independently associated with increased mortality, the vitamin D associated survival benefit maintained within each metabolite quintile. 23 PTH receptors have been found in many immunologic cells (neutrophils, B and T lymphocytes). In a study conducted with patients who had primary hyperparathyroidism, T-cell function was examined before parathyroidectomy and at the first month after parathyroidectomy. It was determined that the total T lymphocyte count and CD4/CD8 ratio were low, the CD8 lymphocyte count was increased and T lymphocyte capability was low before operation. These abnormalities were shown to be improved in the postoperative period and it was concluded that PTH is an immunosuppressive hormone. 24 In another study, a total of 25 HD patients who never had any comorbodities was included, and even though T-cell proliferation after stimulation with staphylococcal enterotoxin B (SEB) was impaired in HD patients (mean serum iPTH value was 301.5 pg/ml ranging from 10 to 1256), it was concluded that PTH, which has been inculpated for many uremic complications, may possibly not contribute to the decreased T-cell-dependent immune response in this population. 25 However, the clinical importance of these findings has still not been clear. 26 Age, immunosuppressive drugs and nutritional status may affect TST response. Several studies have shown that TST response is influenced by nutritional status. 27 Increased, inflammatory load, suppression of albumin synthesis and catabolism also increases risk of malnutrition in CKD. There have been some studies emphasizing on the relationship between anergy and protein intake in HD patients, and between low albumin levels and TST response. [27] [28] [29] In addition, in patients with protein calorie malnutrition undergoing HD and was investigated in response to intradermal antigens and it was detected there was no correlation between anergy and malnutrition. 30 In our study, BMI, which is one of the clinical indicators of malnutrition, was evaluated and no difference was found between the patients who had positive and negative TST. In addition, it was observed that total protein and albumin levels in CKD patients with negative TST were similar to the patients with positive TST.
In conclusion, this study is the first study which showed a correlation between TST negativity and increased PTH levels and receiving vitamin D treatment, because of increased PTH, in CKD patients undergoing HD. Starting from this point, it was concluded that PTH may suppress the immune system and especially cellular immunity. 
